{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:27:37Z","timestamp":1791559657076,"version":"4.3.4"},"reference-count":125,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81922064"],"award-info":[{"award-number":["81922064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874290"],"award-info":[{"award-number":["81874290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91853109"],"award-info":[{"award-number":["91853109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803755"],"award-info":[{"award-number":["81803755"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2019JDRC0091"],"award-info":[{"award-number":["2019JDRC0091"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2019YFSY0038"],"award-info":[{"award-number":["2019YFSY0038"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.apsb.2020.05.004","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T21:53:37Z","timestamp":1590184417000},"page":"355-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"title":["Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers"],"prefix":"10.1016","volume":"11","author":[{"given":"Tingting","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.05.004_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.apsb.2020.05.004_bib2","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-2954A","article-title":"Abstract 2954A: a potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants","volume":"76","author":"Kozaki","year":"2016","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.05.004_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.05.004_bib4","series-title":"c-Met modulators and methods of use","author":"Bannen","year":"2011"},{"key":"10.1016\/j.apsb.2020.05.004_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/350158a0","article-title":"Tyrosine phosphorylation and tyrosine kinase activity of the TRK proto-oncogene product induced by NGF","volume":"350","author":"Kaplan","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.05.004_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0092-8674(91)90628-C","article-title":"The TRKB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3","volume":"66","author":"Klein","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.05.004_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q","article-title":"Nerve growth factor: two receptors, multiple functions","volume":"20","author":"Frade","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/j.apsb.2020.05.004_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(00)80899-5","article-title":"Development of sensory neurons in the absence of NGF\/TRKA signaling in\u00a0vivo","volume":"25","author":"Patel","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2020.05.004_bib9","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1523\/JNEUROSCI.5123-04.2005","article-title":"ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin","volume":"25","author":"Teng","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2020.05.004_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Canc Discov"},{"key":"10.1016\/j.apsb.2020.05.004_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.05.013","article-title":"Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma","volume":"365","author":"Cr\u00e9ancier","year":"2015","journal-title":"Canc Lett"},{"key":"10.1016\/j.apsb.2020.05.004_bib12","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2020.05.004_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PAS.0000000000000537","article-title":"Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion","volume":"40","author":"Sk\u00e1lov\u00e1","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.apsb.2020.05.004_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2020.05.004_bib15","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1182\/blood.V114.22.5042.5042","article-title":"Spliceosomal targeting in acute myeloid leukemia cells with ETV6-NTRK3 fusion","volume":"22","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2020.05.004_bib16","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/j.1460-2075.1996.tb00698.x","article-title":"A splice variant of the neurotrophin receptor TRKB with increased specificity for brain-derived neurotrophic factor","volume":"15","author":"Strohmaier","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2020.05.004_bib17","first-page":"1802","article-title":"Expression of the neurotrophin receptor TRKA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells","volume":"62","author":"Eggert","year":"2002","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.05.004_bib18","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/onc.2009.61","article-title":"TRKA overexpression enhances growth and metastasis of breast cancer cells","volume":"28","author":"Lagadec","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2020.05.004_bib19","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK proteins in clinical cancer therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2020.05.004_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2020.05.004_bib21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: first global approval","volume":"79","author":"Al Salama","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2020.05.004_bib22","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1038\/onc.2011.133","article-title":"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours","volume":"30","author":"Rajan","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2020.05.004_bib23","unstructured":"Phase 1 study of PLX7486 as single agent in patients with advanced solid tumors. ClinicalTrails.gov, 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01804530."},{"key":"10.1016\/j.apsb.2020.05.004_bib24","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.18632\/oncotarget.6547","article-title":"Significant blockade of multiple receptor tyrosine kinases by MGCD516 (sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma","volume":"7","author":"Patwardhan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2020.05.004_bib25","unstructured":"A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of DS-6051b. ClinicalTrials.gov, 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02279433."},{"key":"10.1016\/j.apsb.2020.05.004_bib26","unstructured":"A phase I\/IIa open-label, dose escalation and cohort expansion trial of oral TSR-011 in patients with advanced solid tumors and lymphomas. ClinicalTrials.gov, 2019. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02048488."},{"key":"10.1016\/j.apsb.2020.05.004_bib27","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1535-7163.MCT-14-1105","article-title":"Altiratinib inhibits tumor arowth, invasion, angiogenesis, and microenviroment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2","volume":"14","author":"Smith","year":"2015","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.004_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor Entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Canc Discov"},{"key":"10.1016\/j.apsb.2020.05.004_bib29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Canc Discov"},{"key":"10.1016\/j.apsb.2020.05.004_bib30","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0959-8049(16)32675-2","article-title":"TPX-0005, a novel ALK\/ROS1\/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants","volume":"69","author":"Cui","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.apsb.2020.05.004_bib31","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1158\/1078-0432.CCR-17-1623","article-title":"Foretinib overcomes entrectinib resistance associated with the NTRK1G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model","volume":"10","author":"Nishiyama","year":"2018","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.apsb.2020.05.004_bib32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.apsb.2019.10.003","article-title":"Targeting autophagy-related protein kinases for potential therapeutic purpose","volume":"10","author":"Xiang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.05.004_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0092-8674(91)90419-Y","article-title":"The TRK protooncogene encodes a receptor for nerve growth factor","volume":"65","author":"Klein","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.05.004_bib34","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0092-8674(91)90442-2","article-title":"TRKC, a new member of the TRK family of tyrosine protein kinases, is a receptor for neurotrophin-3","volume":"66","author":"Lamballe","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.05.004_bib35","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.apsb.2019.06.010","article-title":"Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.05.004_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-642-45106-5_5","article-title":"TRK receptors","volume":"220","author":"Deinhardt","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.apsb.2020.05.004_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"TRK receptor tyrosine kinases: a bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Canc Lett"},{"key":"10.1016\/j.apsb.2020.05.004_bib38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35093019","article-title":"Molecular mechanisms of nociception","volume":"413","author":"Julius","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.05.004_bib39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbr.2012.03.010","article-title":"Infusion of BDNF into the nucleus accumbens of aged rats improves cognition and structural synaptic plasticity through PI3K-ILK-Akt signaling","volume":"231","author":"Li","year":"2012","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.apsb.2020.05.004_bib40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/gcc.22200","article-title":"Functional characterization of NTRK1 mutations identified in melanoma","volume":"53","author":"Miranda","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.apsb.2020.05.004_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016871","article-title":"Functional characterization of human cancer-derived TRKB mutations","volume":"6","author":"Geiger","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2020.05.004_bib42","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-10-3034","article-title":"Role and relevance of TRKB mutations and expression in non-small cell lung cancer","volume":"17","author":"Harada","year":"2011","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.apsb.2020.05.004_bib43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/humu.20707","article-title":"Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung","volume":"29","author":"Marchetti","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.apsb.2020.05.004_bib44","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1182\/blood-2007-09-113027","article-title":"Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia","volume":"111","author":"Tomasson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2020.05.004_bib45","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1128\/MCB.20.23.8655-8666.2000","article-title":"Identification and characterization of an activating TRKA deletion mutation in acute myeloid leukemia","volume":"20","author":"Reuther","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2020.05.004_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2217\/14796694.1.5.689","article-title":"Alternative TRKAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma","volume":"1","author":"Tacconelli","year":"2005","journal-title":"Future Oncol"},{"key":"10.1016\/j.apsb.2020.05.004_bib47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2004.09.011","article-title":"TRKA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma","volume":"6","author":"Tacconelli","year":"2004","journal-title":"Canc Cell"},{"key":"10.1016\/j.apsb.2020.05.004_bib48","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.05.004_bib49","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/en.2002-221002","article-title":"The signaling adapters sibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins","volume":"144","author":"Ranzi","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2020.05.004_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/1097-4652(200101)186:1<35::AID-JCP1003>3.0.CO;2-X","article-title":"IRS-1 and IRS-2 are recruited by TRKA receptor and oncogenic TRK-T1","volume":"186","author":"Miranda","year":"2001","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.apsb.2020.05.004_bib51","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bjc.6600544","article-title":"Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc","volume":"87","author":"Roccato","year":"2002","journal-title":"Br J Canc"},{"key":"10.1016\/j.apsb.2020.05.004_bib52","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.05.004_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000023","article-title":"Gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.apsb.2020.05.004_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27271","article-title":"Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma","volume":"65","author":"Halalsheh","year":"2018","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.apsb.2020.05.004_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1093526617712639","article-title":"Infantile NTRK-associated mesenchymal tumors","volume":"21","author":"Davis","year":"2018","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.apsb.2020.05.004_bib56","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2020.05.004_bib57","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2013-2092","article-title":"Abstract 2092: the ALK inhibitor NMOL\/LS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models","volume":"73","author":"Ardini","year":"2013","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.05.004_bib58","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/1471-2164-14-818","article-title":"Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data","volume":"14","author":"Shah","year":"2013","journal-title":"BMC Genom"},{"key":"10.1016\/j.apsb.2020.05.004_bib59","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jnci\/djv306","article-title":"Sensitivity to Entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer","volume":"108","author":"Sartore Bianchi","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2020.05.004_bib60","doi-asserted-by":"crossref","first-page":"39028","DOI":"10.18632\/oncotarget.5494","article-title":"NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2020.05.004_bib61","doi-asserted-by":"crossref","first-page":"55353","DOI":"10.18632\/oncotarget.19512","article-title":"Identification and characterization of a novel rearrangement in a colorectal cancer patient","volume":"8","author":"Milione","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2020.05.004_bib62","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.JTO.0000473485.38553.f0","article-title":"Durable clinical response to Entrectinib in NTRK1-rearranged non-small cell lung cancer","volume":"10","author":"Farago","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.apsb.2020.05.004_bib63","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2020.05.004_bib64","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.05.004_bib65","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.05.004_bib66","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ng.2734","article-title":"The integrated landscape of driver genomic alterations in glioblastoma","volume":"45","author":"Frattini","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2020.05.004_bib67","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2020.05.004_bib68","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.05.004_bib69","first-page":"1457","article-title":"High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma","volume":"4","author":"Bongarzone","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2020.05.004_bib70","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1128\/MCB.15.11.6118","article-title":"The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain","volume":"15","author":"Greco","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2020.05.004_bib71","first-page":"237","article-title":"TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas","volume":"7","author":"Greco","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2020.05.004_bib72","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez Cuesta","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.05.004_bib73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncol"},{"key":"10.1016\/j.apsb.2020.05.004_bib74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1440-1827.2011.02759.x","article-title":"Case report of mammary analog secretory carcinoma of the parotid gland","volume":"62","author":"Ito","year":"2012","journal-title":"Pathol Int"},{"key":"10.1016\/j.apsb.2020.05.004_bib75","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1097\/PAS.0000000000000487","article-title":"Secretory breast carcinoma: a histopathologic and genomic spectrum characterized by a joint specific ETV6-NTRK3 gene fusion","volume":"39","author":"Del Castillo","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.apsb.2020.05.004_bib76","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Canc Cell"},{"key":"10.1016\/j.apsb.2020.05.004_bib77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/djv307","article-title":"Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals an LMNA-NTRK1 gene fusion responsive to crizotinib","volume":"108","author":"Wong","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2020.05.004_bib78","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0298-184","article-title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2020.05.004_bib79","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.05.004_bib80","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1365-2559.2006.02400.x","article-title":"Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma","volume":"48","author":"Anderson","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.apsb.2020.05.004_bib81","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1021\/acsmedchemlett.5b00050","article-title":"(R)-2-Phenylpyrrolidine substituted imidazopyridazines: a new class of potent and selective pan-TRK inhibitors","volume":"6","author":"Choi","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.004_bib82","series-title":"NCCN clinical practice guidelines in oncology: non-small cell lung cancer (2019. V3)","author":"David","year":"2019"},{"key":"10.1016\/j.apsb.2020.05.004_bib83","series-title":"NCCN clinical practice guidelines in oncology: colon cancer (2019. V1)","author":"Aib","year":"2019"},{"key":"10.1016\/j.apsb.2020.05.004_bib84","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of Entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.004_bib85","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.004_bib86","series-title":"Japan becomes the frst country to approve Roche's per sonalised medicine Rozlytrek","author":"Roche","year":"2019"},{"key":"10.1016\/j.apsb.2020.05.004_bib87","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm3005866","article-title":"The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer","volume":"55","author":"Lewis","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.004_bib88","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e19005","article-title":"Phase (Ph) 1\/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations","volume":"32","author":"Weiss","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.05.004_bib89","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/bph.12112","article-title":"Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood\u2013brain barrier","volume":"169","author":"Albanese","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2020.05.004_bib90","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1158\/1535-7163.MCT-10-0190","article-title":"Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy","volume":"9","author":"Albanese","year":"2010","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.004_bib91","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1021\/jm9006559","article-title":"Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor","volume":"52","author":"Brasca","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.004_bib92","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S1359-6349(08)72508-4","article-title":"574 Poster identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the TRK kinase pathway","volume":"6","author":"Thress","year":"2008","journal-title":"Eur J Cancer Supplements"},{"key":"10.1016\/j.apsb.2020.05.004_bib93","doi-asserted-by":"crossref","first-page":"7247","DOI":"10.1021\/jm060897w","article-title":"1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile","volume":"49","author":"Fancelli","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.004_bib94","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1016\/j.bmcl.2006.04.003","article-title":"Discovery of novel isothiazole inhibitors of the TRKA kinase: structure\u2212activity relationship, computer modeling, optimization, and identification of highly potent antagonists","volume":"16","author":"Lippa","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.004_bib95","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/bkcs.10862","article-title":"Identification of pyrrole[3,4-c]pyrazoles as potent tropomyosin receptor kinase A (TRKA) inhibitors","volume":"37","author":"Hyeonjeong","year":"2016","journal-title":"Bull Kor Chem Soc"},{"key":"10.1016\/j.apsb.2020.05.004_bib96","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10637-010-9584-2","article-title":"Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in\u00a0vitro and in\u00a0vivo","volume":"30","author":"Han","year":"2012","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.apsb.2020.05.004_bib97","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1021\/jm5006429","article-title":"Maximizing diversity from a kinase screen: identification of novel and selective pan-TRK inhibitors for chronic pain","volume":"57","author":"Stachel","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.004_bib98","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1535-7163.MCT-09-0499","article-title":"BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R\/IR","volume":"8","author":"Carboni","year":"2009","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.004_bib99","series-title":"Compounds and compositions useful for treating disorders related to NTRK","author":"Wenglowsky","year":"2017"},{"key":"10.1016\/j.apsb.2020.05.004_bib100","series-title":"Compounds and compositions useful for treating disorders related to NTRK","author":"Wenglowsky","year":"2017"},{"key":"10.1016\/j.apsb.2020.05.004_bib101","series-title":"Amino pyrazolopyrimidine compound used as a neurotrophic factor tyrosine kinase receptor inhibitor","author":"Zhu","year":"2018"},{"key":"10.1016\/j.apsb.2020.05.004_bib102","series-title":"Substituted (2-azabicyclo[3.1.0]hexan-2-yl)pyrazolo[1,5-a]pyrimidine and imidazo[1,2-b]pyridazine compounds as TRK kinases inhibitors","author":"Liu","year":"2019"},{"key":"10.1016\/j.apsb.2020.05.004_bib103","series-title":"Imidazo[1,2-b]pyridazinemacrocyclic kinase inhibitor","author":"Li","year":"2019"},{"key":"10.1016\/j.apsb.2020.05.004_bib104","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/ml200261d","article-title":"Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models","volume":"3","author":"Albaugh","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.004_bib105","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.004_bib106","series-title":"Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors","author":"Lieberman","year":"2016"},{"key":"10.1016\/j.apsb.2020.05.004_bib107","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1021\/acs.jmedchem.6b00850","article-title":"The discovery of a potent, selective, and peripherally restricted pan-TRK inhibitor (PF-06273340) for the treatment of pain","volume":"59","author":"Skerratt","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.004_bib108","series-title":"Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors","author":"Lieberman","year":"2019"},{"key":"10.1016\/j.apsb.2020.05.004_bib109","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cellsig.2010.05.012","article-title":"Crosstalks between the receptors tyrosine kinase EGFR and TRKA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation","volume":"22","author":"El Zein","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2020.05.004_bib110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/13543770902721261","article-title":"TRK kinase inhibitors as new treatments for cancer and pain","volume":"19","author":"Wang","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2020.05.004_bib111","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1021\/jm3002982","article-title":"Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as TRK inhibitors with anticancer and antiangiogenic activities","volume":"55","author":"Hong","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.004_bib112","series-title":"Compositions and methods thereof","author":"Stachel","year":"2015"},{"key":"10.1016\/j.apsb.2020.05.004_bib113","series-title":"Dihydronaphtho[2,3-b]benzofuran derivative","author":"Tomizawa","year":"2017"},{"key":"10.1016\/j.apsb.2020.05.004_bib114","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1535-7163.MCT-17-1180","article-title":"Selective TRK inhibitor CH7057288 against TRK fusion-driven cancer","volume":"17","author":"Tanaka","year":"2018","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.004_bib115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/13543776.2020.1737011","article-title":"Tropomyosin receptor kinase inhibitors: an updated patent review for 2016\u20132019","volume":"30","author":"Bailey","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2020.05.004_bib116","doi-asserted-by":"crossref","first-page":"TPS3146","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3146","article-title":"First-time in-human study of VMD-928, an allosteric and irreversible TRKA selective inhibitor, in patients with solid tumors or lymphoma","volume":"37(15_suppl)","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.05.004_bib117","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/acschembio.9b00126","article-title":"Deciphering the allosteric binding mechanism of the human tropomyosin receptor kinase A (hTRKA) inhibitors","volume":"14","author":"Subramanian","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2020.05.004_bib118","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/jm061112p","article-title":"Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase","volume":"50","author":"Cee","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.004_bib119","series-title":"Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors","author":"Allen","year":"2012"},{"key":"10.1016\/j.apsb.2020.05.004_bib120","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1073\/pnas.1611577114","article-title":"Structural characterization of nonactive site, TRKA-selective kinase inhibitors","volume":"114","author":"Su","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.05.004_bib121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.apsb.2020.05.004_bib122","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.apsb.2020.05.004_bib123","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.apsb.2020.01.003","article-title":"Small-molecule MDM2\/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives","volume":"10","author":"Fang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.05.004_bib124","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1021\/acs.molpharmaceut.9b00673","article-title":"TRKC-targeted kinase inhibitors and PROTACs","volume":"16","author":"Zhao","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2020.05.004_bib125","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.cclet.2020.03.028","article-title":"New techniques and strategies in drug discovery","volume":"31","author":"Du","year":"2020","journal-title":"Chin Chem Lett"}],"updated-by":[{"DOI":"10.1016\/j.apsb.2022.02.028","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000}}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520305864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520305864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T07:47:49Z","timestamp":1754984869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383520305864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":125,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2211383520305864"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.05.004","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}